Stonegate Capital Partners has updated its coverage on Alpha Cognition Inc. following the company's fourth quarter and full year 2025 financial results. The biopharmaceutical company demonstrated substantial progress with its product ZUNVEYL, which showed increasingly durable traction in the long-term care market throughout the fiscal year.
Alpha Cognition exited FY25 with ZUNVEYL achieving $2.5 million in net product revenue during the fourth quarter alone, bringing total FY25 revenue to $10.2 million, including $6.8 million specifically from ZUNVEYL sales. More significantly, demand indicators continued to show positive inflection, with bottles dispensed rising 62% quarter-over-quarter to 4,941 units. December 2025 reached a record 1,859 bottles dispensed in a single month, indicating accelerating adoption as the year concluded.
The company's performance in long-term care facilities suggests ZUNVEYL is moving beyond early trial use and becoming more embedded in standard treatment protocols. This is supported by strong repeat ordering behavior, with 729 ordering homes showing 82% repeat orders and 865 prescribers demonstrating 69% repeat prescription writing. These metrics indicate healthcare providers are incorporating the treatment into ongoing patient care rather than using it as a one-time intervention.
Alpha Cognition's financial position appears stable for continued growth, with the company ending FY25 with $66.0 million in cash, providing runway into 2027. Management expects continued sequential sales growth throughout 2026 as ZUNVEYL adoption expands further within the long-term care market. The full announcement with additional details is available at https://www.stonegateinc.com.
This development matters because it signals potential progress in treating cognitive conditions within vulnerable populations in institutional settings. As the global population ages and long-term care facilities face increasing demand, effective treatments that demonstrate durable adoption could significantly impact patient care quality and healthcare economics. The strong repeat ordering patterns suggest ZUNVEYL is providing perceived clinical value that warrants continued use rather than being abandoned after initial trials.
The implications extend beyond Alpha Cognition's financial performance to potential shifts in how cognitive conditions are managed in institutional settings. If ZUNVEYL continues to gain protocol adoption, it could influence treatment standards across the long-term care industry and potentially create new benchmarks for cognitive care in similar environments. The company's cash position provides runway to further scale commercialization efforts, which could accelerate broader market penetration if clinical outcomes support continued adoption.
For investors and industry observers, these results indicate Alpha Cognition is successfully navigating the challenging transition from clinical development to commercial adoption in a specialized healthcare segment. The combination of strong revenue growth, increasing prescription volume, and sustainable financial resources positions the company to potentially expand its impact within the cognitive healthcare market while addressing significant unmet needs in long-term care facilities.
